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Summary. The association between antiphospholipid anti-
bodies and an increased risk of thrombosis in antipho-
spholipid syndrome (aPS) patients is probably caused by
numerous mechanisms, including the effects of antibodies
to phospholipid-binding proteins such as b2-glycoprotein I
and prothrombin. In this study, we investigated the
inhibition of tissue factor pathway inhibitor (TFPI) in 33
patients with primary antiphospholipid syndrome (PAPS).
TFPI was measured in PAPS patients using an amidolytic
assay, dependent on the generation of activated factor X
(Fxa), and this was compared with 55 healthy subjects.
Functional levels of TFPI (mean ^ SD) were significantly
lower in PAPS patients (0·89 ^ 0·37 U/ml) than the
control group (1·05 ^ 0·15 U/ml) (P  0·02). The differ-
ence was caused by a subset of five patients who had TFPI
levels below the lower 99% confidence interval of the
normal reference range, representing increased FXa gen-
eration in the assay system. IgG fractions were isolated from
these five patients and five control subjects, then incorpo-
rated into normal plasma to measure FXa generation in the
TFPI assay system. FXa generation was increased when
polyclonal rabbit anti-human TFPI IgG (P , 0·0001) or
PAPS IgG (P  0·0001) were added to normal plasma,
demonstrating inhibition of TFPI. The apparent anti-TFPI
activity demonstrated in the five subjects with PAPS in this
study may represent a significant new mechanism for
thrombosis in patients with aPS, as it implies that increased
tissue factor FVIIa-mediated thrombin generation might
occur.
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The antiphospholipid syndrome (aPS) is defined as the
association of circulating autoimmune antiphospholipid anti-
bodies (aPL) with arterial or venous thrombosis, recurrent fetal
loss or thrombocytopenia (Hughes et al, 1986; Harris et al,
1987; Love & Santoro, 1990; Wilson et al, 1999). aPL are
directed against phospholipid-binding proteins including b2-
glycoprotein (b2GPI) and prothrombin, and include lupus
anticoagulant (LA) and anticardiolipin antibodies (aCL)
(McNeil et al, 1990). Other, as yet unidentified, target
antigens may be involved in aPS, and could include
components of the tissue factor (TF) pathway of coagulation.
Recent evidence suggests that upregulation of the TF pathway
may be important in contributing to the hypercoagulability
seen in aPS (Amengual et al, 1998). Reports by Adams et al
(1995) who described decreased tissue factor pathway
inhibitor (TFPI) activity in patients with lupus anticoagu-
lants, and Salemink et al (2000) who reported enhanced FXa
generation in three aPS patients in the presence of b2GPI,
antibodies to b2GPI and TFPI, support this evidence.
TFPI regulates the initiation of the tissue factor pathway
by forming a quaternary complex (TF–FVIIa–FXa–TFPI)
after the exposure of TF to the circulation (Broze et al,
1988). Upregulation of the TF pathway could potentially be
caused by decreased TFPI activity or by an antibody to TFPI,
contributing to the hypercoagulability in patients with aPS.
In this paper, we report the presence of anti-TFPI activity in
five subjects with primary antiphospholipid syndrome
(PAPS), which could contribute to the thrombotic events
in these patients.
PATIENTS AND METHODS
Patients and samples
Venous blood was collected with minimal stasis from 33
well characterized subjects with PAPS (Exner et al, 1991;
Greaves et al, 2000). Blood was collected into empty tubes
for the preparation of serum, or Vacutainers (Becton
Dickinson, Oxford, UK) containing 0·105 mol/l tri-sodium
citrate. Plasma was prepared by centrifuging at 2000 g for
15 min at room temperature. The plasma was separated
and centrifuged again to ensure platelet depletion. Serum
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and double-spun plasma samples were stored in aliquots at
2708C until required.
Antiphospholipid antibody testing
Lupus anticoagulant. LA was detected according to
standard criteria (Greaves et al, 2000) using a commercial
kit for the dilute Russell’s Viper Venom Time, with a platelet
neutralization procedure (Unicorn Diagnostics, London,
UK).
Anticardiolipin antibodies. IgG and IgM antibodies to
cardiolipin were measured in serum samples using an
enzyme-linked immunosorbent assay (ELISA) technique
using microtitre plates (Polysorp, Nunc, Life Technologies,
Paisley, UK) coated with cardiolipin (bovine heart, Sigma-
Aldrich, Poole, UK). Assays were standardized using
standard sera calibrated against the appropriate Interna-
tional Reference Material (Harris & Hughes, 1987).
Anti-b22GPI antibodies. Anti-b2GPI IgG was measured by
ELISA, using a commercial kit (Diastat antib2GPI, Axis-
Shield Diagnostics, Dundee, UK) based on a method
previously developed in our laboratory (McNally et al,
1995). Anti-b2GPI IgM was assayed by an adaptation of the
IgG kit components to accommodate the detection of IgM
antibodies by using a m-specific conjugated secondary
antibody. Assays were standardized using serum with a
known high concentration of antibody.
Antiprothrombin antibodies. Antiprothrombin IgG and IgM
were analysed by ELISA using m-irradiated microtitre plates
(Maxisorp, Nunc, Life Technologies, Paisley, UK) coated
overnight at 48C with 10 mg/ml human prothrombin
(Enzyme Research Laboratories, Swansea, UK) in phos-
phate-buffered saline (PBS) (0·01 mol/l phosphate,
0·145 mol/l NaCl, pH 7·2). Blocking was performed using
PBS containing 0·1% Tween 20 and 1% bovine serum
albumin (BSA; Sigma-Aldrich, Poole, UK) for 1 h at room
temperature. Plates were then washed once using PBS
containing 0·1% Tween 20. A standard curve was prepared
from reference plasma with a known high-aPT activity. Test
samples were diluted 1:50 in PBS containing 0·1% Tween
20 and 1% BSA. Next, 100 ml of standard or test was added
to duplicate wells for 1 h at room temperature. After three
washes, 100 ml of alkaline phosphatase-conjugated anti-
human IgG or IgM was added for 1 h. p-Nitrophenyl
phosphate (100 ml; Sigma-Aldrich, Poole, UK) in diethano-
lamine buffer (pH 9·8) was added and incubated at 378C for
colour development, which was stopped using 3 mol/l
NaOH, and the absorbance read at 405 nm.
All assays were validated by the inclusion of internal
quality control samples of known activity. The cut-off point
for the upper limit of normal was determined as the
geometric mean 1 95% Confidence Interval (CI) of values
obtained in at least 30 apparently healthy adults.
TFPI activity assay
TFPI was measured using an amidolytic assay based on the
method of Sandset et al (1987). Briefly, 25 ml of diluted test
or standard plasma was incubated with 100 ml of reaction
mixture containing equal amounts of recombinant TF
(diluted 1/40) (Innovin, Dade Behring, Marburg, Germany),
0·013 U/ml FVII (Sigma-Aldrich,), 0·03 U/ml FX (Enzyme
Research Laboratories) and 0·075 mol/l CaCl2, in flat-
bottomed microtitre plates (Alpha Laboratories, Eastleigh,
UK). After incubation for 10 min at 378C, 50 ml of substrate
mixture containing FX (0·6 U/ml) and an amidolytic
substrate for FXa (S-2222, 2·7 mmol/l; Chromogenix,
Mo¨lndal, Sweden) was added and incubated at 378C for a
further 30 min. The reaction was stopped by the addition of
50 ml of 50% acetic acid. The TFPI activity assay was
standardized using Immuno Reference Plasma 100%
(Technoclone, Vienna, Austria). Results were derived from
the mean of duplicate tests for all assays. The reference
range was defined as the mean ^3 standard deviations.
Protein G chromatography
The IgG fraction was isolated from plasma by affinity
purification on a Protein G column according to the
manufacturer’s instructions (Pharmacia Biotech, St Albans,
UK). Samples were diluted 1 in 5 in PBS pH 7·4 and applied
to a pre-equilibrated Protein G column. Bound IgG was
eluted with glycine buffer, pH 2·8 and collected in 4 ml
fractions containing 0·6 ml 1·0 mol/l Tris. Fractions
containing protein were pooled, dialysed to PBS and
concentrated using an Amicon concentrator and a PM30
membrane. The protein concentration was determined by
measuring the absorbance with a 1 cm light path and an
extinction coefficient of E1%,1cm  13·6, aliquoted and
stored at 2708C.
IgG mixing studies
IgG fractions were isolated from the five PAPS subjects with
increased FXa activity in the functional TFPI assay, and five
normal controls. The fractions were mixed with normal
plasma for 30 min at 378C to a final concentration of
10 mg/ml and then assessed for functional TFPI activity. A
rabbit anti-human polyclonal TFPI antibody (American
Diagnostica, Greenwich, USA) was used in this system as a
control to determine loss of TFPI activity in the normal
plasma.
Statistical analysis
Between-group differences in functional TFPI were analysed
using the student’s two tailed t-test for unpaired data. P-
values , 0·05 were considered statistically significant.
RESULTS
Patients – clinical and laboratory details
Patients in this study were well characterized and did not
have acute ongoing thrombotic events. These included 25
female and 8 male patients, mean age 47·8 ^ 14·4 years
(range 25–74 years). Twenty-six (79%) patients had a
clinical history of thrombosis (58% venous; 21% arterial),
20 (61%) were unequivocally LA-positive, 20 (61%) had
anti-ß2GPI IgG/M antibodies, 16 (48%) antiprothrombin
IgG/M antibodies and 25 (76%) anticardiolipin IgG/M
antibodies.
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TFPI levels
The laboratory normal range for the functional TFPI assay
was established using plasma from 55 healthy subjects (37
men, 18 women; mean age  44·2 years) with no apparent
haemostatic abnormality. The reference range was 0·60–
1·50 U/ml (mean  1·05 U/ml; standard devia-
tion  0·15 U/ml) (Fig 1).
Mean functional TFPI levels were 0·89 ^ 0·37 U/ml in
33 subjects with PAPS, which was significantly lower than
levels in the normal subjects (P  0·02) (Fig 1). The lower
functional TFPI in the subject group was caused by a
subpopulation of samples (n  5), which generated
increased FXa activity (below the lower 99% confidence
interval of the reference range). Three of these patients were
receiving warfarin and aspirin, one was receiving aspirin
only and one was receiving warfarin only as part of
thromboprophylaxis because of previous events. No patient
received heparin as part of their treatment.
Table I summarizes the major clinical and laboratory
details of the five patients that demonstrated increased FXa
activity in the functional assay for TFPI.
TFPI inhibition
TFPI activity in normal plasma was 100% inhibited after
30 min at 378C by the addition of a polyclonal rabbit anti-
human TFPI antibody (10 mg/ml). When the IgG
fractions from the five selected patients was mixed with
normal plasma, the mean TFPI activity was reduced from
0·99 U/ml to 0·72 U/ml (P  0·0001) (Fig 2). In each
case, this represented a reduction of greater than 25% TFPI
activity, and the effect was demonstrated on two separate
occasions. When IgG (0–20 mg/ml) from one of the five
PAPS subjects with low TFPI activity was added to normal
plasma, TFPI activity was reduced in a concentration-
dependent manner (Fig 3). Control IgG (final concentra-
tion  10 mg/ml) collected from five normal subjects
demonstrated less than 1% reduction (0·98 U/ml) in TFPI
activity when mixed with normal plasma.
DISCUSSION
There have been varying reports in the literature on TFPI
levels in patients with aPS. TFPI antigen levels have been
reported to be both higher (Amengual et al, 1998; Wakita
et al, 1999), and lower (Kiraz et al, 1999), compared with
the control groups. Although these variations have yet to be
Fig 1. Functional TFPI in normal and PAPS subjects. Bar indicates
lower 99% confidence interval of the normal reference range.
Table I. Comparison of laboratory characteristics of PAPS subjects with normal (n  28) and decreased (n  5) TFPI activity in the functional
assay for TFPI.
PAPS subjects
Normal TFPI activity
(n  28)
Decreased TFPI activity
(n  5)
Sex (M:F) 6:22 3:2
Arterial thrombosis 3 (11) 4 (80)
Venous thrombosis 19 (68) 0 (0)
" Anti-b2GPI
IgG 14 (50) 4 (80)
IgM 9 (32) 1 (20)
" Antiprothrombin
IgG 7 (25) 1 (20)
IgM 23 (82) 5 (100)
" Anticardiolipin
IgG 20 (71) 2 (40)
IgM 8 (29) 3 (60)
Lupus-anticoagulant positive 17 (61) 3 (60)
TFPI (U/ml) 1·05 ^ 0·17 0·13 ^ 0·23
Percentages are given in parenthesis.
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explained, it is feasible that an upregulation of coagulation,
with increased levels of both TFPI and TF, could contribute
to thrombosis in patients with aPS. Alternatively, if there is
an imbalance between TF and TFPI levels, an increased risk
of thrombosis may result owing to low levels of TFPI in the
presence of normal or elevated TF.
Decreased TFPI activity in patients with LA has
previously been demonstrated in an in vitro assay system
(Adams et al, 1995; Adams & Oostryck, 1997). The
increased FXa generated in this system was abolished with
the addition of excess amounts of thromboplastin. This
inferred that LA preferentially targeted the phospholipid
component of the assay, and was associated with decreased
TFPI inhibition of TF–FVIIa–FXa. It was concluded that
both the amount and source of thromboplastin used in this
particular system affected the measurement of functional
TFPI in patients with LA.
Subsequent reports have implicated the inhibition of TFPI
anticoagulant activity by strong lupus anticoagulants
(Jacobsen et al, 1999), and described enhanced FXa
generation in three patients with aPS that was dependent
on the presence of b2GPI, antibodies to b2GPI and TFPI
(Salemink et al, 2000). Perhaps of most significance is a
recent report on the presence of anti-TFPI antibodies in
patients with aPS (Cakir et al, 2000). These antibodies were
associated with stroke and arterial thrombosis, but not with
other classical clinical features of aPS such as venous
thrombosis.
In this study of a cohort of 33 PAPS patients, we report
increased FXa generation (and, therefore, apparent TFPI
reduction), as measured in a functional assay for TFPI. The
statistical difference between PAPS patients and normal
volunteers was caused by a small (n  5) subset of the
patient population. When these five patients were removed
from the statistical analysis, there was no significant
difference in functional TFPI levels. Four of the five patients
had a history of arterial disease, but none had venous
thromboembolism, in keeping with the results of Cakir et al
(2000).
We also demonstrated inhibition of TFPI activity after the
addition of IgG fractions from the same five PAPS patients to
normal plasma. The reduction in TFPI activity was
consistently greater than 25%, and was reproduced on
two separate occasions. The increased generation of FXa is
evidence of anti-TFPI activity in the IgG fraction from the
selected PAPS patients.
The anti-TFPI activity demonstrated in this study is
further evidence of an autoantibody to TFPI. Identification
of a specific pathological anti-TFPI antibody will probably be
confirmed with continued screening of IgG and/or IgM
fractions from aPS patients, and the use of affinity
chromatography for anti-TFPI. IgM anti-TFPI antibodies
may be present in blood samples from PAPS patients and
could explain some of the observed discrepancies between
TFPI activity in patient plasma and the degree of inhibition
of TFPI in mixing experiments of normal plasma and patient
IgG. The presence of an anti-TFPI antibody in the plasma
from patients with aPS patients would provide an explana-
tion to the discrepant results of earlier reports (Adams et al,
1995; Adams & Oostryck, 1997). Anti-TFPI antibodies may
contribute towards the overall pathophysiological mechan-
isms of thrombosis in aPS patients. Indeed, in this study all
five patients that demonstrated anti-TFPI activity also had a
history of arterial thrombosis and/or stroke. Future work
will be required to determine the incidence, clinical
significance and the association with other antiphospholipid
antibodies.
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